Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $5.8 million.

  • Day One Biopharmaceuticals' Accounts Payables rose 9151.47% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 9151.47%. This contributed to the annual value of $3.3 million for FY2024, which is 2663.04% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Accounts Payables of $5.8 million as of Q3 2025, which was up 9151.47% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Accounts Payables registered a high of $16.0 million during Q4 2022, and its lowest value of $439000.0 during Q2 2022.
  • In the last 4 years, Day One Biopharmaceuticals' Accounts Payables had a median value of $4.0 million in 2022 and averaged $4.5 million.
  • The largest annual percentage gain for Day One Biopharmaceuticals' Accounts Payables in the last 5 years was 93986.33% (2023), contrasted with its biggest fall of 8384.95% (2023).
  • Quarter analysis of 4 years shows Day One Biopharmaceuticals' Accounts Payables stood at $16.0 million in 2022, then crashed by 83.85% to $2.6 million in 2023, then rose by 26.63% to $3.3 million in 2024, then surged by 77.13% to $5.8 million in 2025.
  • Its Accounts Payables was $5.8 million in Q3 2025, compared to $5.1 million in Q2 2025 and $2.5 million in Q1 2025.